Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement

In typical hemolytic uremic syndrome (HUS) approximately 25% of patients show central nervous system (CNS) involvement often leading to serious long-term disabilities. We used the C5-complement inhibitor Eculizumab as rescue therapy. From 2011 to 2014, 11 children (median age 22 months, range 11–175...

Descripción completa

Detalles Bibliográficos
Autores principales: Pape, Lars, Hartmann, Hans, Bange, Franz Christoph, Suerbaum, Sebastian, Bueltmann, Eva, Ahlenstiel-Grunow, Thurid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
6200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616562/
https://www.ncbi.nlm.nih.gov/pubmed/26091445
http://dx.doi.org/10.1097/MD.0000000000001000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616562/
https://www.ncbi.nlm.nih.gov/pubmed/26091445
http://dx.doi.org/10.1097/MD.0000000000001000

Ejemplares similares